Insulet (NASDAQ:PODD) Upgraded at Wall Street Zen

Insulet (NASDAQ:PODD - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Friday.

PODD has been the subject of several other reports. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective for the company in a research report on Tuesday, May 13th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Royal Bank of Canada started coverage on Insulet in a report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target for the company. Stifel Nicolaus boosted their price target on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Finally, Citigroup reiterated a "buy" rating and issued a $380.00 price target (up from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Three research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $318.41.

Insulet Stock Performance

Shares of NASDAQ PODD traded down $1.71 during midday trading on Friday, reaching $323.29. 50,631 shares of the company were exchanged, compared to its average volume of 704,355. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet has a 1 year low of $172.07 and a 1 year high of $329.33. The stock has a fifty day simple moving average of $277.81 and a 200 day simple moving average of $272.24. The stock has a market cap of $22.75 billion, a P/E ratio of 55.84, a PEG ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.73 EPS. On average, research analysts forecast that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PODD. Blue Trust Inc. raised its holdings in Insulet by 117.3% in the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after acquiring an additional 149 shares during the period. Swedbank AB increased its holdings in shares of Insulet by 152.9% during the 4th quarter. Swedbank AB now owns 53,688 shares of the medical instruments supplier's stock worth $14,016,000 after purchasing an additional 32,456 shares during the period. Baader Bank Aktiengesellschaft acquired a new stake in shares of Insulet during the 4th quarter valued at about $234,000. OLD National Bancorp IN acquired a new stake in shares of Insulet during the 4th quarter valued at about $215,000. Finally, Mediolanum International Funds Ltd boosted its position in shares of Insulet by 32.7% during the 4th quarter. Mediolanum International Funds Ltd now owns 8,890 shares of the medical instruments supplier's stock valued at $2,336,000 after acquiring an additional 2,189 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.